An ongoing clinical trial of Wave Life Sciences’ WVE-004 in people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with C9orf72 gene mutations has been expanded to evaluate a quarterly dose of the medication. The decision to administer WVE-004 every three months was based on the potency and…
Read more
The ALS Society of Canada and Brain Canada are supporting four early-career scientists who are working to advance an understanding of amyotrophic lateral sclerosis (ALS) and treatments for people with the disease. Grants totaling CA$390,000 (about $290,000) will fund projects by three doctoral students and one postdoctoral…
An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS). The oral compound, also known as TUDCA, is one of the two ingredients in Relyvrio (sodium phenylbutyrate…
People who took part in clinical testing of NurOwn, a cell therapy for amyotrophic lateral sclerosis (ALS), and family members have sent a letter in support of Brainstorm Cell Therapeutics and its investigational therapy to the U.S. Food and Drug Administration (FDA). They are also asking for an…
For columnist Juliet Taylor, the gift of presence is more important than material things. Just being there is enough.
Visit the ALS News Today forums to connect with others in the ALS community.
Becoming educated and informed about ALS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ALS journey.
There is no cure for ALS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
